Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (235)	3/27/2001 1:54:41 PM
From: Dave	Respond to of 370

Thanks for the update, Jim. I hope Kessman can indeed find additional funding, because if he says the coffers will be dry in just about a year, that means that layoffs and cost-cutting measures will have to begin well before that. So let's hope he is able to find some strong funding in the next six months. Man, this stock has been volatile lately! Up 15% one day, down 15% the next, back down, back up, on no news. My gut feeling is that investors are excited but nervous about VION's prospects, so when the broad stock market goes up a little bit, VION shoots skyward, and when the broad market declines a hair, VION plummets. Dave

To: Jim Oravetz who wrote (235)	3/29/2001 12:56:32 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion Says Phase I Trials Show Triapine Well Tolerated Dow Jones Newswires NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) said results from two Phase I clinical trials show that Triapine is well tolerated and can be given safely daily for five days, every other week, in patients with advanced cancer. In a press release Wednesday, Vion said the two Phase I trials of Triapine, which is a small molecule ribonucleotide reductase inhibitor, were designed to determine the maximum tolerated dose and optimal schedule in advanced cancer patients who had failed prior treatments and lacked effective treatment options. Two patients with advanced tumors who had failed prior treatment showed at least a 50% reduction in a serum tumor marker when given the maximum tolerated dose. Vion said the data is sufficient to justify the beginning of Phase II trials in selected diseases. The biopharmaceutical company is proceeding with Phase I trials combining Triapine with other anticancer agents, and is exploring continuous infusion regimens, which Vion said may be even more effective.